Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026
Regulatory
Today, on 3 February 2026, the extraordinary general meeting was held in EQL Pharma AB. A summary of the adopted resolution follows below.
Welcome to EQL Pharma's Investor Pages!
We strive to have an open and proactive dialogue with our shareholders.
Read MoreInterim Report Q2 2025/2026
Listen to CEO Axel Schörling present EQL Pharma's latest report.
Interim Report Q2 2025/2026Press Releases
Interim Report April – December 2025
Regulatory
During the quarter, sales rose to SEK 118.9 million, an increase of 29% from SEK 92.2 million in the previous year. This represents a new record quarter for EQL
Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26
EQL Pharma AB (publ) will publish its interim report for the third quarter, 2025/26, on Tuesday, February 3[rd].
EQL Pharma in Short
EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals.
Read more about usFinancial Calendar
08May2026
Year End Report Q4
20Aug2026
Annual General Meeting 2026